Promising results for faricimab revealed in TENAYA, LUCERNE year 2 data
Scott Walter, MD, an investigator in the TENAYA and LUCERNE trials discusses the year 2 data for the treat-and-extend regimen of faricimab for the treatment of nAMD and DME.
New optics textbook aims to be a compendium resource for the topic
At AAO, Kamran Riaz, MD, discussed the new textbook, "Optics for the New Millennium," which is intended to be a compendium resource for ophthalmologists.
Moving beyond the drop: CEO provides updates on Oyster Point's pipeline
Jeff Nau, PhD, MMS, President and CEO of Oyster Point Pharmaceuticals, provides an appraisal of the company's pipeline as well as updates on recent innovations to hit the market.
ViaLase seeks to disrupt glaucoma treatment paradigm with new femtosecond laser treatment
Shawn O'Neil of ViaLase shares updates on the company's femtosecond laser, image-guided, high-precision trabeculotomy (FLigHT) treatment.
Contralateral eye study investigates iStent vs Hydrus stent for glaucoma
At AAO 2022, Mitch Shultz, MD, provides discourse on iStent inject vs Hydrus contralateral eye evaluation data.
Trukera Medical rebranding allows team to expand into the broader corneal health market
Adam Szaronos, President and CEO of Trukera Medical, discusses the recent rebranding of TearLab as well as the launch of the ScoutPro Osmolarity System.
Assessing the effectiveness of netarsudil and episcleral blood flow in treatment-naive glaucoma suspects, hypertension subject
Osamah Saeedi, MD, MS, discusses his AAO 2022 talk titled, "Single-Cell Erythrocyte Tracking in Human Subjects Reveals Increase in Episcleral Venous Flow With Netarsudil 0.02%."
Higher rates of repeat corneal crosslinking need found in younger patients
At AAO 2022, Philip Dockery, MD, MPH, presents, "Effectiveness of corneal crosslinking in young patients."
Robot-assisted micro interventional glaucoma surgery reduces surgeon's tremors
Gautam Kamthan, MD, presented data at AAO 2022 regarding robot-assisted micro interventional glaucoma surgery.
Choosing among DSAEK, DMEK and DSO for endothelial keratoplasty
Kathryn A. Colby, MD, PhD, sits down with Ophthalmology Times to discuss her 2022 AAO presentation: "Endothelial Keratoplasty Should I Choose? DSAEK, DMEK, DSO"
Post hoc analysis of varenicline solution OC-01 shows promise for dry eye patients undergoing anticholinergic therapy
At AAO 2022 in Chicago, Illinios, Christopher Starr, MD, presented a talk entitled, "Efficacy of OC-01 (varenicline solution) (VNS) 0.03mg for Treatment of Dry Eye Disease Signs and Symptoms in Subjects With and Without Antidepressant/ Anxiolytic Use: Post-hoc Analysis of ONSET-1 and ONSET-2 Clinical Trials."
Positive visual outcomes reported one year following monocular implantation of small aperture IOL
Mark H. Blecher, MD, dives into his AAO 2022 topic: "One-Year Visual Outcomes Following Monocular Implantation with a Small Aperture IOL."
Discussing how fluid dynamic affect visual acuity in wet macular degeneration
At the 2022 American Academy of Ophthalmology meeting, Justis Ehlers, MD, presented a talk titled, "Defining the Fluid Problem in Neovascular AMD: To Dry or Not to Dry?"
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Novel glasses, designed for children with cranial dysotosis, help doctors provide functional eyewear for children in underserved communities, says Donny Suh, MD.
Reviewing the AAO cornea preferred practice patterns: Corneal edema, opacifications, ectasia and bacterial keratitis
David Hutton discusses the AAO 2022 presentation, "Corneal Edema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with speaker Francis S. Mah, MD.
Dispersive ophthalmic viscosurgical device found to be safe, effective in clinical trials
Mark Packer, MD, speaks on his 2022 AAO poster: "Safety and Effectiveness of a New FDA-Approved Dispersive Ophthalmic Viscosurgical Device."
Visus Therapeutics CEO announces acquisition of ViewPoint Therapeutics to expand on cataract, presbyopia candidate
Ben Bergo, CEO of Visus Therapeutics, announced the acquisition of all patents and other assets of ViewPoint Therapeutics, which will accelerate development of novel alpha-crystallin chaperone compounds as a non-surgical treatment for age-related cataracts.
Faricimab: YOSEMITE, RHINE treat-and-extend data illustrate favorable personalized treatment dynamics for the treatment of DME
Roger A. Goldberg, MD, MBA, discusses his 2022 AAO poster: "T&E-Based Personalized Treatment Interval Dynamics in the YOSEMITE/RHINE Trials of Faricimab in DME."
Poll results: Are you attending AAO in Chicago?
Results from our recent poll regarding AAO 2022 attendance indicate that most ophthalmologists and retina specialists plan to participate in the Annual Meeting in person in Chicago, Illinois.
POLL: Are you attending AAO in Chicago?
We're polling ophthalmologists about attendance at the 2022 American Academy of Ophthalmology Meeting in Chicago, Illinois. The poll is now closed.
Wykoff: RGX-314 highlights DRSS improvements in patients diagnosed with DME, NPDR
Charles Wykoff, MD, took the stage at the American Society of Retina Specialists annual meeting in New York to present a talk titled “Suprachoroidal Delivery of RGX-314 Gene Therapy for Diabetic Retinopathy: Phase II ALTITUDE Study.” He discusses results of the trial, which showed improvements for patients diagnosed with diabetic macular edema and non-proliferative diabetic retinopathy, with notable improvements according to the Diabetic Retinopathy Severity Scale.
Use of aflibercept in the management of diabetic retinopathy
Lloyd Clark, MD, highlights his ASRS presentation focusing on the PANORAMA study detailing the use of aflibercept in the management of diabetic retinopathy.
What the impact of 44-week aflibercept data may mean in a real-world setting
David Brown, MD, highlights his ASRS poster that includes 44-week data for a four-times-higher dose of aflibercept in a real-world setting.
VIEW 1 and VIEW 2 studies: taking a deeper dive
Rahul Khurana, MD, shares a preview of his ASRS poster based on an analysis of the second year of the VIEW 1 and VIEW 2 studies comparing aflibercept and ranibizumab treatment arms.
Study: Using OCT Doppler to measure retinal blood flow biomarkers
The study assess retinal blood biomarkers using a new prototype OCT, aiming to measure retinal biomarkers such as blood flow volume, average velocity, and vessel diameter with a new prototype.
Machine learning may predict optimal treatment regimen for patients with nAMD
Carlos Quezada Ruiz, MD, senior medical director at Genentech, discusses “Predicting optimal treatment regimen for patients with neovascular age-related macular degeneration using machine learning.”
GA therapy endpoints: Should tissue preservation be considered?
As novel therapies in the pipeline are aiming to decrease the rate of GA expansion—the endpoint Karl Csaky, MD and Fredrick Ferris III, MD, identified in 2007—Dr. Csaky reinforces on the importance of preserving the central retinal tissue.
RNA-Seq analysis identifies cell subtypes to use as models for corneal wound healing
At ARVO 2022 in Denver, Colorado, Timothy Blenkinsop, MD, presented “3D Eye Organoids with Distinct Cornea.” His presentation outlined how these organoids have developed sophisticated cornea structures.
Phase 3 PEACHTREE, AZALEA integrated study results presented at ARVO 2022: BCVA gains, CST reduction with Xipere
The Phase 3 integrated PEACHTREE and AZALEA study data revealed strong safety and efficacy for triamcinolone acetonide via suprachoirodal injection.
New PRO instrument helps measure patient experience with therapies such as anti-VEGF agents, lasers to treat their eye disease
Diana Do, MD, professor of ophthalmology at Stanford's Byers Eye Institute, presents research on a newly developed, novel patient-reported outcome instrument (PRO) for patients who have proliferative diabetic retinopathy and who are undergoing treatment with either intravitreal anti-VEGF therapy, or panretinal photocoagulation.
2 Clarke Drive Cranbury, NJ 08512